Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations

ConclusionsThese results add to the growing body of evidence that darunavir-based therapy could be simplified to reduce costs and toxicity, as well as to improve patient compliance. However, the heterogeneity in pharmacokinetic response should be considered when assessing whether individual patients could benefit from a particular regimen, for instance through the use of population pharmacokinetic models.Clinical Trial RegistrationClinicalTrials.gov identifier: NCT03101644, date of registration: 5 April, 2017.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research